Physician profile
Peter O Ojuro
NPI 1992919559
$3,511.43
in general payments reported to CMS, 2019-2025
30 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $215 · 2021: $607 · 2022: $567 · 2023: $762 · 2024: $779 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713 · Education: $36.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.82 |
| Education | $36.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.36 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $846.34 | 2019-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $206.01 | 2023-2025 | |
| Janssen Biotech, INC. | $137.63 | 2019-2024 | Stelara, Simponi, Remicade |
| Ironwood Pharmaceuticals, INC | $130.65 | 2019-2024 | Linzess |
| Celgene Corporation | $121.07 | 2021-2024 | Zeposia |
| Cook Medical LLC | $107.16 | 2019 | |
| Phathom Pharmaceuticals, INC. | $80.39 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $75.26 | 2022-2023 | Dupixent |
| Daiichi Sankyo INC. | $74.39 | 2021-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $73.46 | 2019-2023 | Entyvio |
| Pfizer INC. | $66.22 | 2019-2025 | |
| Qol Medical, LLC | $64.78 | 2023-2024 | Sucraid, Sucraid |
| Enterra Medical, INC. | $64.24 | 2025 | |
| Boston Scientific Corporation | $62.29 | 2019-2025 | General - Therapies |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $56.91 | 2020-2023 | |
| Vivus LLC | $52.40 | 2021 | |
| Lilly USA, LLC | $43.10 | 2024 | Omvoh |
| Redhill Biopharma INC. | $35.13 | 2020-2021 | |
| Alfasigma USA, INC. | $35.05 | 2020 | |
| Ardelyx, INC. | $34.90 | 2024-2025 | Ibsrela |
| Henry Schein, INC. | $33.53 | 2024 | |
| Intercept Pharmaceuticals, INC. | $32.44 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $28.78 | 2022-2023 | |
| Madrigal Pharmaceuticals | $21.27 | 2024 | Resmetirom |
| Merck Sharp & Dohme LLC | $17.46 | 2022 | |
| Evoke Pharma, INC. | $17.37 | 2022 | |
| Shire North American Group INC | $16.67 | 2019 | |
| Fresenius Kabi USA, LLC | $15.61 | 2024 | Idacio |
| Glaxosmithkline, LLC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ojuro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.